Literature DB >> 16210110

Human papillomavirus infections of the genital and respiratory tracts in young children.

Sara H Sinal1, Charles R Woods.   

Abstract

Human papillomavirus (HPV) causes papillomas (warts) on the skin and respiratory mucosal surfaces (laryngeal and oral papillomas) in addition to condyloma acuminata (anogenital warts). HPV has become one of the most common sexually transmitted diseases in adults. Vertical transmission from mother to infant during birth is well recognized. Laryngeal papillomas are the most common tumors of the larynx in children worldwide, and recurrent lesions are common occurrences. Anogenital warts in children are problematic in that child sexual abuse is a potential means of acquisition, but many cases are acquired perinatally. Postnatal acquisition by nonsexual means also can occur. The likelihood of sexual abuse as the mode of acquisition increases with increasing age in childhood. The virus infects primarily epithelial cells, where it can exist as a long-term latent infection that can reactivate or persist actively (even subclinically), with resultant accumulation of host chromosomal mutations. The latter accounts for the oncogenic potential of a number of HPV types, and childhood infections may lead to neoplasia later in life. Regression of papillomas over the course of months to years is the usual natural course. Numerous treatments are available, but most do not prevent persistent infection or problematic recurrences. Multivalent HPV vaccines have been developed, and early results of clinical trials appear to be very promising.

Entities:  

Mesh:

Year:  2005        PMID: 16210110     DOI: 10.1053/j.spid.2005.06.010

Source DB:  PubMed          Journal:  Semin Pediatr Infect Dis        ISSN: 1045-1870


  15 in total

1.  Anogenital Warts in Childhood - Always a Marker for Sexual Abuse?

Authors:  S Bussen; M Sütterlin; U Schmidt; D Bussen
Journal:  Geburtshilfe Frauenheilkd       Date:  2012-01       Impact factor: 2.915

2.  Transplacental Transmission of Human Papillomavirus.

Authors:  Anca Florina Zgura; Elvira Bratila; Simona Vladareanu
Journal:  Maedica (Buchar)       Date:  2015-06

3.  Association of E6AP (UBE3A) with human papillomavirus type 11 E6 protein.

Authors:  Nicole Brimer; Charles Lyons; Scott B Vande Pol
Journal:  Virology       Date:  2006-10-04       Impact factor: 3.616

4.  Maternal condyloma acuminata infection in pregnancy and offspring long-term respiratory and infectious outcome.

Authors:  Ofir Sahar; Gil Gutvirtz; Tamar Wainstock; Eyal Sheiner
Journal:  Arch Gynecol Obstet       Date:  2022-06-01       Impact factor: 2.344

Review 5.  Human papilloma virus (HPV) infection in children and adolescents.

Authors:  Ioannis N Mammas; George Sourvinos; Demetrios A Spandidos
Journal:  Eur J Pediatr       Date:  2008-12-03       Impact factor: 3.183

6.  High-risk human papillomavirus in the oral cavity of women with cervical cancer, and their children.

Authors:  Rajan Saini; Tan P Khim; Sarah A Rahman; Mazian Ismail; Thean H Tang
Journal:  Virol J       Date:  2010-06-16       Impact factor: 4.099

Review 7.  Is administration of the HPV vaccine during pregnancy feasible in the future?

Authors:  Abbey B Berenson; Pooja R Patel; Alan D Barrett
Journal:  Expert Rev Vaccines       Date:  2013-11-28       Impact factor: 5.217

8.  HPV genotypes in the oral cavity/oropharynx of children and adolescents: cross-sectional survey in Poland.

Authors:  Julia Durzyńska; Joanna Pacholska-Bogalska; Maria Kaczmarek; Tomasz Hanć; Magdalena Durda; Magdalena Skrzypczak; Anna Goździcka-Józefiak
Journal:  Eur J Pediatr       Date:  2010-11-24       Impact factor: 3.183

9.  The role of NH4Cl and cysteine proteases in Human Papillomavirus type 16 infection.

Authors:  Sarah A Dabydeen; Patricio I Meneses
Journal:  Virol J       Date:  2009-07-20       Impact factor: 4.099

10.  Transplacental transmission of Human Papillomavirus.

Authors:  Renato L Rombaldi; Eduardo P Serafini; Jovana Mandelli; Edineia Zimmermann; Kamille P Losquiavo
Journal:  Virol J       Date:  2008-09-25       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.